---
title: "ACA Collapse · Supply Chain Transmission: Insurance and Pharmaceuticals"
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/43155954.md"
description: "The collapse of the ACA affects not only hospitals—insurance companies are directly hurt, and pharmaceutical companies suffer indirect but significant impact. The line between winners and losers is very clear. I. Insurance Sector: Clear Winners and Losers 🔴 Loser #1: ACA Exchange Insurers — Direct Hit What Happened: After enhanced subsidies expired, enrollment in exchanges plummeted by about 20%. This is a direct revenue loss for insurance companies..."
datetime: "2026-08-03T12:42:41.000Z"
locales:
  - [en](https://longbridge.com/en/topics/43155954.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/43155954.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/43155954.md)
author: "[罗莱夏朵](https://longbridge.com/en/profiles/14860395.md)"
generator: "portal-rs"
---

# ACA Collapse · Supply Chain Transmission: Insurance and Pharmaceuticals

> The collapse of the ACA affects not only hospitals — insurance companies are directly hurt, and pharmaceutical companies suffer an indirect but significant impact. The line between winners and losers is very clear.

* * *

## I. Insurance Sector: Clear Winners and Losers

### 🔴 Loser #1: ACA Exchange Insurers — Direct Hit

**What Happened**: After enhanced subsidies expired, enrollment in exchanges plummeted by approximately 20%. This represents a direct revenue loss for insurers.

| Company                    | Q2 2026 Impact                                                      | Stock Price Reaction         | Risk Level                                  |
| -------------------------- | ------------------------------------------------------------------- | ---------------------------- | ------------------------------------------- |
| $Molina Healthcare(MOH.US) | 🔴 **Unexpected Loss** — "surging health benefit costs"              | Plummeted to near 6-year low | 🔴🔴🔴 Most Vulnerable                         |
| $Centene(CNC.US)           | 🔴 Loss + Expected continued loss of ACA members throughout the year | Fell but partially priced in | 🔴🔴 Largest ACA Underwriter                  |
| $Oscar Health(OSCR.US)     | 🔴 Cut full-year guidance, medical costs soaring                     | Severely Hit                 | 🔴🔴🔴 Highest Concentration (Almost Pure ACA) |
| $Elevance Health(ELV.US)   | 🟠 Significant decline in exchange members, but diversified business | Moderate Pressure            | 🟠 Diversification Buffer                    |

**Key Mechanism — "Adverse Selection Spiral"**:

`Subsidy Expiration → Healthy people drop coverage (unwilling to pay double premiums) → Those remaining in plans are those needing medical services (risk pool deteriorates) → Medical loss ratio (MLR) soars → Insurers incur losses → Insurers either raise prices (accelerating dropouts) or exit the market → Death Spiral`

**Evidence**: Centene mentioned "unexpected acuity shifts" — people remaining in exchange plans are sicker than expected, leading to soaring payout ratios. This is exactly the standard characteristic of adverse selection.

### 🟢 Winner #1: Medicare Advantage — Benefiting from Demographics

**Logic**: ACA primarily covers individuals under 65. Medicare Advantage covers those 65+. ACA collapse → does not directly affect MA. However, there is an **indirect benefit**:

| Company               | MA Positioning                        | 2026 Trend                                                       |
| --------------------- | ------------------------------------- | ---------------------------------------------------------------- |
| $Unitedhealth(UNH.US) | Largest in MA (but shrinking)         | Divested 930k MA members in 2026 (profit over scale)             |
| $Humana(HUM.US)       | Second largest in MA, growing rapidly | +25% YoY individual MA growth, may surpass UNH to become largest |
| $CVS Health(CVS.US)   | Mid-tier MA + Pharmacy + PBM          | Diversified, slight MA growth                                    |

**Indirect Benefit Logic**:

1.  ACA collapse → Decreased purchasing power for ages 60-64 → Immediate transition to MA at age 65 → Increased MA growth rate
2.  Hospital financial pressure → Enhanced bargaining power of MA plans relative to providers
3.  But: MA also faces risk of payment cuts by the Trump administration (potential flat rate in 2027)

**Comprehensive Assessment**: HUM > UNH > CVS. However, the MA sector as a whole is not a "clean" beneficiary of the ACA collapse — MA has its own payment policy risks.

### 🟡 To Be Determined #3: Medicaid Managed Care — Second Wave Impact in 2027

| Company                | Medicaid Exposure            | 2027 Risk                                     |
| ---------------------- | ---------------------------- | --------------------------------------------- |
| **Centene (CNC)**      | Largest Medicaid MCO         | 🔴 If 2027 work requirements strip 4.1M people |
| **Molina (MOH)**       | Highly dependent on Medicaid | 🔴 Same as above                               |
| **Elevance (ELV)**     | Significant exposure         | 🟠                                             |
| **UnitedHealth (UNH)** | Moderate                     | 🟡                                             |

**Timing**: Medicaid work requirements take effect in 2027 → CBO predicts stripping 4.1M people → This will be a risk priced in starting Q3-Q4 2026. Currently, the market has not focused on this.

### Overall Insurance Sector Judgment

| Rating               | Ticker        | Direction | Logic                                                                  |
| -------------------- | ------------- | --------- | ---------------------------------------------------------------------- |
| 🔴 Short              | MOH (Molina)  | ↓         | Direct ACA hit + Already losing + Medicaid second-wave risk            |
| 🔴 Short              | OSCR (Oscar)  | ↓         | Pure ACA company → Subsidy expiration = Crisis                         |
| 🟠 Cautious           | CNC (Centene) | ↓         | Dual exposure to ACA+Medicaid, but large scale allows adjustment room  |
| 🟢 Relatively Bullish | HUM           | ↑/→       | MA growth benefits from demographics, but has own payment policy risks |
| 🟢 Safest             | UNH           | →         | Optum diversification (not pure insurance) + MA scale advantage        |

* * *

## II. Pharmaceutical Sector: Indirect but Notable

### 💊 Big Pharma (LLY, NVO, PFE, MRK, etc.) — Mild Impact but Negative Direction

**Core Logic**: Revenue for big pharma comes mainly from:

1.  Commercial/Employer Insurance (→ Unaffected)
2.  Medicare Part D (→ Unaffected)
3.  Medicaid (→ Affected in 2027)
4.  Cash/Self-pay (→ Unaffected)
5.  ACA Exchange Plans (→ **Directly Affected, but small share**)

**Quantitative Estimate**: ACA covers about 21 million people (before subsidy expiration), with estimated prescription drug spending of about $30-40 billion/year. 2.6 million dropping coverage → Approximately \*\*$4-6 billion in prescription drug demand disappears\*\* (about 1-2% of the US prescription drug market). Impact on individual companies depends on the proportion of ACA patients in their product mix.

### 🔬 Specific Ticker Analysis

#### Eli Lilly (LLY) — Minimal Impact

| Factor             | Assessment                                                                                                                                                                              |
| ------------------ | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Core Products**  | Mounjaro (Diabetes) + Zepbound (Weight Loss) — GLP-1 Duo                                                                                                                                |
| **Revenue Source** | Primarily Commercial Insurance (70%), Medicare Part D(15%), Cash Self-pay (~10%), ACA/Medicaid(<5%)                                                                                     |
| **ACA Exposure**   | **Very Low** — Weight loss indication for GLP-1 (Zepbound) is often excluded or not covered in ACA plans                                                                                |
| **LillyDirect**    | $349-499/month self-pay channel — If more people become uninsured, some may switch to self-pay (Neutral to Positive for LLY)                                                            |
| **Lilly Cares**    | Free drug assistance (Only Mounjaro for diabetes, income qualified) — Increase in uninsured patients → Higher assistance costs → But this is a charity project, does not affect revenue |
| **Overall Rating** | 🟢 Almost Immune                                                                                                                                                                         |

**Key Risks**: Not ACA, but pricing pressure + CagriSema competition (Novo Nordisk) + GLP-1 patent cliff (2030s). ACA collapse has almost no direct impact on LLY.

#### Novo Nordisk (NVO) — Minimal Impact

| Factor               | Assessment                                                                        |
| -------------------- | --------------------------------------------------------------------------------- |
| **Core Products**    | Ozempic/Wegovy (semaglutide) + CagriSema (pipeline)                               |
| **Market Position**  | Suppressed by LLY's tirzepatide — LLY holds 60% of US weight loss market          |
| **ACA Exposure**     | Similar to LLY, Very Low                                                          |
| **Self-pay Pricing** | Wegovy ~$650/month self-pay (NovoCare) — Higher than LLY                          |
| **CagriSema**        | Just lost head-to-head trial to tirzepatide — This is a much larger risk than ACA |
| **Overall Rating**   | 🟢 ACA Immune, but CagriSema failure is a bigger structural risk                   |

#### Other Big Pharma

| Ticker                  | ACA/Medicaid Exposure                                                                       | Rating              |
| ----------------------- | ------------------------------------------------------------------------------------------- | ------------------- |
| **Pfizer (PFE)**        | Moderate (Eliquis, Ibrance, Prevnar — Chronic disease drugs used heavily by ACA population) | 🟠 Slightly Negative |
| **Merck (MRK)**         | Low (Keytruda — Oncology drug, hospital management, primarily Medicare)                     | 🟢                   |
| **AbbVie (ABBV)**       | Low (Humira/Skyrizi — Specialty drugs, primarily commercial insurance)                      | 🟢                   |
| **Bristol Myers (BMY)** | Moderate (Eliquis same as PFE)                                                              | 🟠                   |
| **J&J (JNJ)**           | Very Low (Diversified healthcare, drugs are just one part)                                  | 🟢                   |
| **AstraZeneca (AZN)**   | Low (Oncology + Respiratory, primarily Medicare+ Commercial)                                | 🟢                   |

* * *

## III. Indirect Transmission: Hospital Financial Pressure → Drug Demand

This is the **overlooked transmission chain**:

`Hospital Bad Debt Soars (HCA -$1B+) → Hospitals Cut Costs:    ├─ Delay Equipment Purchases (ISRG da Vinci) ✓ Confirmed   ├─ Reduce Elective Surgeries → Reduce Pre/Post-op Drugs   ├─ Reduce Hospitalizations → Reduce In-hospital Drug Usage   └─ More Aggressive Drug Price Negotiations → Compress Pharma Profit Margins`

### Which Drug Categories Are Most Affected

| Drug Category                                                                     | ACA Collapse Impact                                      | Representative Pharma                     |
| --------------------------------------------------------------------------------- | -------------------------------------------------------- | ----------------------------------------- |
| **Elective Surgery Related** (Anesthesia, Post-op Analgesia, Anticoagulants)      | 🟠 Moderate                                               | PFE(Eliquis Post-op Anticoagulation), BMY |
| **Chronic Disease Management** (Antihypertensives, Antidiabetics, Lipid-lowering) | 🔴 High — Uninsured patients stop medication              | PFE, MRK, NVO, LLY                        |
| **Mental Health** (Antidepressants, Anxiolytics)                                  | 🔴 High — Uninsured patients interrupt treatment          | Primarily Generics                        |
| **Oncology/Specialty** (Chemotherapy, Immunotherapy)                              | 🟢 Low — Primarily Medicare, Emergency Hospital Treatment | MRK(Keytruda), BMY(Opdivo)                |
| **Vaccines**                                                                      | 🟢 Low — Covered by Public Health Programs                | PFE, MRNA                                 |
| **GLP-1 Weight Loss**                                                             | 🟢 Very Low — Commercial Insurance/Self-pay               | LLY, NVO                                  |

* * *

## IV. Special Case: GLP-1 and "Self-pay Conversion"

### Counter-intuitive Possibility: GLP-1 Might Benefit?

**Logic Chain**:

1.  2.6 million people lose ACA insurance → Many of them lose insurance plans that cover GLP-1
2.  But GLP-1 weight loss (Zepbound/Wegovy) was already not covered by most ACA plans
3.  If uninsured individuals still want GLP-1 → They switch to LillyDirect/NOVOCare self-pay channels
4.  Self-pay $349-499/month → Pharma profit margins might be higher than insurance reimbursement (Insurance reimbursements have rebates/discounts)

**But this is only theoretical** — In reality, most people losing insurance are price-sensitive individuals who dropped coverage due to doubled premiums. A $349-499/month self-pay GLP-1 is unrealistic for them. Net Effect: Neutral to Negative.

* * *

## V. Short/Long Matrix Summary

### Insurance

| Direction | Ticker   | Strategy            | Catalyst                                      | Risk                             |
| --------- | -------- | ------------------- | --------------------------------------------- | -------------------------------- |
| 🔴 Short   | **MOH**  | Put or Direct Short | Q3 Earnings (Oct) — Expected continued losses | Acquisition Target               |
| 🔴 Short   | **OSCR** | Put                 | Q3 Earnings                                   | Poor Liquidity                   |
| 🟠 Short   | **CNC**  | Put Spread          | Q3+Medicaid 2027 Expectations                 | Large Scale, Has Adjustment Room |
| 🟢 Long    | **HUM**  | Call or Stock       | MA Growth Continues to Beat Expectations      | MA Payment Policy Risk           |
| 🟡 Neutral | **UNH**  | —                   | Optum Moat                                    | Valuation Not Low                |

### Pharmaceuticals

| Direction   | Ticker  | Strategy | Logic                                                                              |
| ----------- | ------- | -------- | ---------------------------------------------------------------------------------- |
| 🟢 Hold/Long | **LLY** | —        | ACA Immune, GLP-1 Duo Structure, 60% Weight Loss Market Share                      |
| 🟡 Cautious  | **NVO** | —        | ACA Immune, but CagriSema Risk Greater Than ACA                                    |
| 🟠 Watch     | **PFE** | Observe  | Dual Exposure to ACA+Elective Surgery, But Already Pressed to Low Levels by Market |

* * *

## VI. Core Conclusion

**Insurance Companies Are the Second Wave Victims of the ACA Collapse** (The First Wave Was Hospitals). MOH/OSCR/CNC Have Already Shown Losses and Downward Guidance.

**Big Pharma (LLY/NVO) Is Almost Immune** to the Direct Impact of the ACA Collapse — GLP-1s Rely on Commercial Insurance and Self-pay.

**But Hospital Financial Pressure → Reduced Drug Demand** Indirect Transmission May Become Significant in 2027. Elective Surgery and Chronic Disease Management Drugs Are Most Affected.

**MA Insurers (HUM) May Unexpectedly Benefit**: ACA Collapse Accelerates Transition of Ages 60-64 to Age 65+ MA.

**2027 Medicaid Work Requirements Are the Second Wave** → CNC and MOH Face Double Whammy.

> \*Le Refuge — Overlooked Corners Series · 2026-08-01

### Related Stocks

- [OSCR.US](https://longbridge.com/en/quote/OSCR.US.md)
- [UNH.US](https://longbridge.com/en/quote/UNH.US.md)
- [CNC.US](https://longbridge.com/en/quote/CNC.US.md)
- [CVS.US](https://longbridge.com/en/quote/CVS.US.md)
- [MOH.US](https://longbridge.com/en/quote/MOH.US.md)
- [ELV.US](https://longbridge.com/en/quote/ELV.US.md)
- [HUM.US](https://longbridge.com/en/quote/HUM.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)

## Comments (3)

- **IDM · 2026-08-05T16:52:55.000Z**: Just pure nonsense 🤔
- **投资小达人 · 2026-08-04T02:53:37.000Z · 👍 1**: The analysis is very comprehensive 👍 How do you guys place orders? Buying A-shares was smooth before, but why is it so laggy when buying US and HK stocks?
  - **坐等个股起飞** (2026-08-04T02:54:33.000Z): You need to flip 🧱, hang a 🪜 or buy an overseas 📱 card


---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**